The Motley Fool
20 Jun 2026, 19:15 UTC · 2h ago
Should You Buy Abbott Labs Stock Hand Over Fist Before July 16?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
The Motley Fool
20 Jun 2026, 19:15 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Abbott Laboratories is scheduled to report second-quarter earnings on July 16. — Earnings dates create short-term volatility and are primary catalysts for price movement in individual stocks.
+0.20The FreeStyle Libre continuous glucose monitoring platform generated approximately $2 billion in Q1 sales. — Strong revenue from a core growth engine supports the company's valuation and long-term earnings potential.
+0.10Abbott's medical device business reached approximately $5.5 billion in Q1 revenue, accounting for roughly half of total sales. — Confirms the company's successful shift toward a medical device-heavy revenue mix, reducing reliance on pharmaceuticals.
+0.05Which stocks this story touches
Continue reading
6 related stories
Top 1 mover · tap to explore
The article highlights strong diversification, significant growth in medical devices, and a large global market opportunity for its glucose monitoring platform.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Market Watch
5h ago
